MK 6349

Drug Profile

MK 6349

Alternative Names: MK6349

Latest Information Update: 27 Jul 2009

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 21 Jul 2009 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (unspecified route)
  • 31 May 2007 Phase-I clinical trials in Type-2 diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top